Research Library
Literature summaries for the compounds we supply — what has actually been published, with every reference verified against National Library of Medicine records. Where the evidence is animal-only, we say so. Where no human trials exist, we say that too.
Study Database
Explore cited literature by compound, year, and evidence model, with links to original sources.
Reconstitution Calculator
Lab math for reconstitution and concentration — solvent volumes, concentrations, and syringe graduations.
About the Library
What these literature summaries are, who they serve, and how they relate to the research materials in the store.
Editorial Policy
How articles are sourced, how PubMed references are checked, and how corrections are handled.
Compound overviews
BPC-157: Research Overview & Study Index
Evidence-focused overview of BPC-157: origin, proposed mechanisms, animal-model findings, and regulatory status, with verified citations.
Updated 2026-09-10Long-acting amylin analog (dual amylin/calcitonin receptor agonist)Cagrilintide: Research Overview & Study Index
Evidence-based overview of cagrilintide (AM833): amylin biology, dual amylin/calcitonin receptor pharmacology, phase 2 monotherapy data, and the CagriSema REDEFINE phase 3 program, with full citations.
Updated 2026-09-10Long-acting GHRH(1-29) analog (albumin-binding growth hormone secretagogue)CJC-1295: Research Overview & Study Index
Evidence-focused overview of CJC-1295 — with-DAC and no-DAC forms — covering GHRH biology, the albumin-binding half-life mechanism, human trial data, and the compound's discontinued clinical history, with verified citations.
Updated 2026-09-10Synthetic pineal tetrapeptide (AEDG) bioregulatorEpitalon: Research Overview & Study Index
Evidence-focused overview of Epitalon (Epithalon): pineal bioregulator origin, telomerase and animal-model findings, human cohort data, and the single-laboratory concentration of the literature, with verified citations.
Updated 2026-09-08Endogenous copper-binding tripeptideGHK-Cu: Research Overview & Study Index
Evidence-focused overview of GHK-Cu: discovery, copper chemistry, proposed mechanisms, skin and wound-model findings, gene-expression research, and study limitations, with verified citations.
Updated 2026-09-08Selective ghrelin receptor (GHS-R1a) agonist — synthetic pentapeptide growth hormone secretagogueIpamorelin: Research Overview & Study Index
Evidence-focused overview of Ipamorelin: its discovery as a selective ghrelin-receptor agonist, human PK/PD data, the discontinued postoperative-ileus clinical program, and animal-model findings, with verified citations.
Updated 2026-09-10GLP-1/glucagon dual receptor agonistMazdutide: Research Overview & Study Index
Evidence-based overview of mazdutide (IBI362/LY3305677): oxyntomodulin-analog mechanism, GLORY and DREAMS phase 3 trial data, Chinese NMPA approvals, with full citations.
Updated 2026-09-10Synthetic cyclic α-MSH analog (non-selective melanocortin receptor agonist)Melanotan II: Research Overview & Study Index
Evidence-focused overview of Melanotan II: the 1990s-2000s human tanning and erectile-function trials, the safety-signal literature, its lineage to two FDA-approved melanocortin drugs, and regulatory status, with verified citations.
Updated 2026-09-10Mitochondrial-derived peptide (16 amino acids)MOTS-c: Research Overview & Study Index
Evidence-focused overview of MOTS-c: mitochondrial-peptide biology, discovery, AMPK and exercise-related mechanisms, the K14Q longevity polymorphism, and regulatory status, with verified citations.
Updated 2026-09-10Endogenous redox coenzyme (pyridine dinucleotide)NAD+: Research Overview & Study Index
Evidence-focused overview of NAD+ (nicotinamide adenine dinucleotide): biology, precursor trial data, direct-administration pharmacokinetics, and open questions, with verified citations.
Updated 2026-09-10Nonselective melanocortin receptor agonistPT-141 (Bremelanotide): Research Overview & Study Index
Evidence-based overview of PT-141/bremelanotide (Vyleesi): nonselective melanocortin receptor mechanism, the male erectile-dysfunction trials that preceded it, RECONNECT phase 3 data in female HSDD, safety profile, and post-approval commercial history, with full citations.
Updated 2026-09-10GLP-1/GIP/glucagon triple receptor agonistRetatrutide: Research Overview & Study Index
Evidence-based overview of retatrutide (LY3437943): mechanism, phase 1-3 trial data, liver and metabolic findings, with full citations.
Updated 2026-09-10Synthetic tuftsin-analog heptapeptideSelank: Research Overview & Study Index
Evidence-focused overview of Selank: tuftsin origin, proposed mechanisms, Russian clinical literature, and regulatory status, with verified citations.
Updated 2026-09-10GLP-1 receptor agonistSemaglutide: Research Overview & Study Index
Evidence-based overview of semaglutide: mechanism, landmark trials (STEP, SUSTAIN, SELECT, FLOW), and open research questions, with citations.
Updated 2026-09-10Synthetic ACTH(4-10) heptapeptide analogSemax: Research Overview & Study Index
Evidence-focused overview of Semax: ACTH-fragment origin, proposed mechanisms, Russian clinical literature versus internationally indexed mechanistic work, and regulatory status, with verified citations.
Updated 2026-09-10Growth hormone-releasing hormone (GHRH) analog — synthetic 29-amino-acid peptide fragmentSermorelin: Research Overview & Study Index
Evidence-focused overview of sermorelin (GRF(1-29)-NH2): the library's only formerly FDA-approved compound, its GHRH mechanism, pediatric and adult trial findings, and current regulatory status, with verified citations.
Updated 2026-09-10Glucagon/GLP-1 dual receptor agonistSurvodutide: Research Overview & Study Index
Evidence-based overview of survodutide (BI 456906): dual glucagon/GLP-1 mechanism, phase 2 obesity and MASH trial data, phase 3 SYNCHRONIZE results, with full citations.
Updated 2026-09-10Synthetic thymosin beta-4 fragment/analogTB-500: Research Overview & Study Index
Evidence-focused overview of TB-500 and thymosin beta-4: actin-binding biology, animal-model findings, the human trial landscape, and doping-control status, with verified citations.
Updated 2026-09-10Growth hormone-releasing hormone (GHRH) analogTesamorelin: Research Overview & Study Index
Evidence-based overview of tesamorelin (Egrifta): stabilized GHRH analog mechanism, pivotal HIV-lipodystrophy trials, visceral/liver fat and cognition research, with full citations.
Updated 2026-09-10GIP/GLP-1 dual receptor agonistTirzepatide: Research Overview & Study Index
Evidence-based overview of tirzepatide (Mounjaro/Zepbound): dual GIP/GLP-1 mechanism, SURPASS and SURMOUNT trial data, cardiovascular and sleep apnea findings, with full citations.
Updated 2026-09-10Head-to-head comparisons
Two (or three) bodies of literature, side by side — including the cases where no head-to-head study exists at all.
BPC-157 vs TB-500: What the Research Shows
Side-by-side, evidence-focused comparison of BPC-157 and TB-500: origins, mechanisms, animal-model findings, human-trial status, and doping rules, with verified citations.
Updated 2026-09-10Cagrilintide vs Semaglutide: What the Research Shows
Side-by-side research comparison of cagrilintide (amylin analog) and semaglutide (GLP-1 receptor agonist): mechanisms, monotherapy trial results, and the CagriSema combination data, with citations.
Updated 2026-09-10CJC-1295 With DAC vs Without DAC: What the Research Shows
A side-by-side look at the two molecules sold under the CJC-1295 name — the DAC-bound long-acting form with published human trial data, and the no-DAC/modified GRF(1-29) form that shares its backbone but not its evidence base — with verified citations.
Updated 2026-09-10Ipamorelin vs GHRP-2 vs GHRP-6: What the Research Shows
How the three ghrelin-receptor-agonist growth hormone secretagogues compare on the one property the literature actually measured head-to-head: hormonal selectivity — plus the discovery lineage, appetite effects, and diagnostic-use history, with verified citations.
Updated 2026-09-10Retatrutide vs Tirzepatide vs Semaglutide: What the Research Shows
Side-by-side research comparison of retatrutide, tirzepatide, and semaglutide: receptor targets, trial results, head-to-head evidence, and what remains unproven, with full citations.
Updated 2026-09-10Sermorelin vs Tesamorelin: What the Research Shows
Two GHRH analogs, opposite regulatory fates: sermorelin's approval and 2008 withdrawal versus tesamorelin's ongoing Egrifta approval, compared on chemistry, trial evidence, and regulatory history with full citations.
Updated 2026-09-10Survodutide vs Mazdutide: What the Research Shows
Side-by-side research comparison of the two leading dual glucagon/GLP-1 receptor agonists: design lineages, SYNCHRONIZE vs GLORY/DREAMS trial data, liver findings, and regulatory geography, with full citations.
Updated 2026-09-10Tirzepatide vs Semaglutide: What the Research Shows
Head-to-head trial data comparing tirzepatide and semaglutide: SURMOUNT-5 weight results, SURPASS-2 glycemic results, cardiovascular outcomes programs, and where each compound's evidence base is deeper — with full citations.
Updated 2026-09-10Get research updates
Subscribe to the Limitless Labs newsletter for research insights and product updates. You can unsubscribe at any time.
Disclaimer: Research materials supplied by Limitless Labs are intended strictly for in-vitro research and laboratory use only. They are not intended for human or animal consumption, therapeutic use, or any form of self-administration. They are not approved medicines. Where this library discusses an approved pharmaceutical, that product is distinct from research materials sold by Limitless Labs. This page is an educational summary of published research and is not medical advice. These statements have not been evaluated by the Food and Drug Administration.